Back
Exhaled eicosanoid profiles in children with atopic asthma and healthy controls.
E. Glowacka, U. Jedynak-Wasowicz, M. Sanak, G. Lis
Pediatr. Pulmonol. 2013 Apr;48(4):324-35.
PubMed: 22782807
Abstract
Chronic endobronchial inflammation is a hallmark of pediatric asthma and involves the arachidonic acid pathway. Its non-volatile metabolites can be quantified in the exhaled breath condensate (EBC), and single substances have been studied as non-invasive biomarkers for the diagnosis and monitoring of children with asthma. The aim of this study was to compare the content and profile of a wider range of eicosanoids in the EBC between patients and a control group. EBC was sampled from 33 children (aged 12.4 ± 3.1 years) with stable atopic asthma (26 on inhaled steroid treatment) and 25 healthy controls (11.8 ± 3.2 years). Validated high performance liquid chromatography coupled with a tandem mass spectrometry platform (HPLC-MS2 ) was used to measure 13 different compounds. In addition, exhaled nitric oxide levels (FeNO) were measured and bronchial hyperresponsiveness (BHR) was assessed by an exercise challenge test in all subjects. An analytical approach was used for multivariate regression modeling of disease status using the most relevant variables. The levels of PGEM (P
Associated compounds:
Compound Name
with link to compound page |
Structure | Number of references |
---|---|---|
Leukotriene C4 | 30 | |
6-Keto-prostaglandin F1 alpha | 15 | |
11-Dehydro-thromboxane B2 | 3 | |
5-HETE | 3 | |
13,14-Dihydro-15-keto-PGE2 | 2 | |
Prostaglandin G2 | 1 | |
11-trans-LTC4 | 1 |